Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02670044 · ClinicalTrials.gov registry record · Phase 1
A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT02670044 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 88 participants.
The verdict
NCT02670044, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
The primary objective for this study is to assess the safety and tolerability as well as preliminary efficacy of venetoclax in combination with cobimetinib, and venetoclax in combination with idasanutlin in patients with relapsed or refractory acute myeloid leukemia (R/R) AML who are not eligible for cytotoxic therapy.
Interventions
- DRUG Venetoclax
- DRUG Cobimetinib
- DRUG Idasanutlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2016-03-09 |
| Est. Completion | 2020-12-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02670044
The ClinicalTrials.gov registry entry for NCT02670044 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT02670044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02670044 about?
NCT02670044 is a clinical study titled "A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy". The primary objective for this study is to assess the safety and tolerability as well as preliminary efficacy of venetoclax in combination with cobimetinib, and venetoclax in combination with idasanutlin in patients with relapsed or refractory acute myeloid leukemia (R/R) AML who are not eligible fo...
What is the current status of trial NCT02670044?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2016-03-09. Estimated completion is 2020-12-10.
What interventions are being tested in trial NCT02670044?
The interventions under investigation include: Venetoclax (DRUG), Cobimetinib (DRUG), Idasanutlin (DRUG).
Who is sponsoring clinical trial NCT02670044?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.